NCT03240445View on ClinicalTrials.gov

Impact of Changing the Dosing Regimen on the PK Profile of ODM-203

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 24, 2017

Primary Completion Date

October 23, 2017

Study Completion Date

October 23, 2017

Conditions
Healthy
Interventions
DRUG

ODM-203 (Period 1)

ODM-203 400mg as tablets taken 30 minutes after food

DRUG

ODM-203 (Period 2)

ODM-203 400mg as tablets taken 1 hour before a light breakfast

DRUG

ODM-203 (Periods 3-6)

ODM- 203 400mg as tablets for oral administration or 400mg as oral dispersion either before/after food

Trial Locations (1)

NG11 6JS

Quotient Clinical Ltd, Nottingham

Sponsors

Collaborators (1)

Quotient Clinical
All Listed Sponsors
collaborator

Quotient Clinical

OTHER

lead

Orion Corporation, Orion Pharma

INDUSTRY